

HPV-avertable cancer risks in India: A pooled analysis of 9 observational studies

Jayadeep Patra^{1,2}, Rajesh Dikshit³, Mehak Bhatia^{1,2}, Chinthanie Ramasundarahettige¹ and Prabhat Jha^{1,2}

¹ Centre for Global Health Research, St Michael's Hospital, Toronto, Canada

² Dalla-Lana School of Public Health, University of Toronto, Toronto, Canada

³ Department of Epidemiology, Tata Memorial Hospital, Mumbai, India

Dear Sir,

We read with great interest the article by Michaud *et al.*¹ "Highrisk HPV types and head and neck cancer." Their research presents the associations between infections with high-risk HPV subtypes and head and neck cancer risk in the US. In addition to HPV16, HPV18/33, and HPV52 emerged as important risk factors for oropharyngeal and oral cancers, respectively.

Oral cancer is the most common form of malignant cancers in the Indian subcontinent; it accounts for one-third of the global burden of oral cancer incidence and mortality.^{2,3} Despite extensive improvements in diagnosis and therapy in recent decades, the prognosis of oral cancers remains poorly understood.⁴ In the Indian sub-populations, oral cancer is primarily associated with commonly known risk factors such as tobacco chewing and bidi or cigarette smoking. However, additional risk factors may be at play, as suggested by the incidence of oral cancer in approximately 20% of the patients, who develop this malignancy without a definite etiology of risk factors.⁵ Similarly, cervical cancer in India constitutes a quarter of the global burden with 132,000 new cases and 74,000 deaths every year.³ It is the leading malignancy in our region with age standardized rates of 14.3 and 7.7 per 100,000 individuals from urban and rural areas, respectively.⁶ Mixed claims have been made regarding the association of HPV infection with the development of both cervical and oral cancers in different regions of India.^{7,8} In addition, limited information is available on the distribution of HPV types in the country. This makes it important to further explore the association between HPV types, and cervical and oral cancers.

Based on the existing literature from the Indian context, we conducted a meta-analysis on the association of HPV and high-risk HPV types on head and neck, and cervical cancer

4 3 2	2916/34 080 (9%) 71/442 (16%) 59/420 (14%)	623/834 (75%) 523/717 (73%)	92%/ 0.93 89%/ 0.41				13.3 (4.8–37.4
3	71/442 (16%)	523/717 (73%)					
		, ,	89%/ 0.41				100/15 70
2	59/420 (14%)						10.9 (1.5-78.4
		218/517 (42%)	59% ()				8.9 (2.2-35.3
5	468/1201 (39%)	460/716 (64%)	40%/ 0.63				3.2 (1.9-5.)
3	380/1013 (38%)	366/529 (69%)	70%/ 0.49	—	_		3.1 (1.3-7.4
1	56/396 (14%)	13/34 (38%)	()				2.7 (1.4-5.4
4	432/1080 (40%)	384/533 (72%)	78%/ 0.01	_			3.8 (1.7-8.
3	371/978 (38%)	339/432 (78%)	87%/ 0.01				3.7 (0.9–15.4
1	56/396 (14%)	13/34 (38%)	()				2.7 (1.4-5.4
	3 1 4 3	 3 380/1013 (38%) 1 56/396 (14%) 4 432/1080 (40%) 3 371/978 (38%) 	 3 380/1013 (38%) 366/529 (69%) 1 56/396 (14%) 13/34 (38%) 4 432/1080 (40%) 384/533 (72%) 3 371/978 (38%) 339/432 (78%) 	3 380/1013 (38%) 366/529 (69%) 70%/ 0.49 1 56/396 (14%) 13/34 (38%) () 4 432/1080 (40%) 384/533 (72%) 78%/ 0.01 3 371/978 (38%) 339/432 (78%) 87%/ 0.01 1 56/396 (14%) 13/34 (38%) ()	3 380/1013 (38%) 366/529 (69%) 70%/ 0.49 1 56/396 (14%) 13/34 (38%) () 4 432/1080 (40%) 384/533 (72%) 78%/ 0.01 3 371/978 (38%) 339/432 (78%) 87%/ 0.01	3 380/1013 (38%) 366/529 (69%) 70%/ 0.49 1 56/396 (14%) 13/34 (38%) () 4 432/1080 (40%) 384/533 (72%) 78%/ 0.01 3 371/978 (38%) 339/432 (78%) 87%/ 0.01 1 56/396 (14%) 13/34 (38%) ()	3 380/1013 (38%) 366/529 (69%) 70%/ 0.49 1 56/396 (14%) 13/34 (38%) () 4 432/1080 (40%) 384/533 (72%) 78%/ 0.01 3 371/978 (38%) 339/432 (78%) 87%/ 0.01 1 56/396 (14%) 13/34 (38%) ()

* Details of the 9 studies included can be obtained from the corresponding author. Studies under head and neck cancer included cancers of lip, tongue, oral cavity, oropharynx, larynx and hypopharynx. † Evidence of significant heterogeneity between studies is noted at I² > 40%. Evidence of significant publication bias is noted at p<0-05.

Figure 1. Meta-analysis of the association between HPV subtypes and cervical and head and neck cancers in India.

492

risk to validate the present findings by the authors. We pooled the odds ratios using a random-effects model for nonfatal head and neck cancers and cervical cancers from patients with HPV infection in nine published studies in the region (Figure 1). Of 1,184 adult males and females with head and neck cancer and 3,750 adult females with cervical cancer, the association with any HPV infection was notable for both head and neck cancer (OR: 3.2, 99% CI: 1.9-5.2) and cervical cancer (OR: 13.3, 99% CI: 4.8-37.4). The association between HPV infection and head and neck cancer in specific sites suggests that the strongest and most consistent association is with oral cancer (OR: 3.8, 99% CI: 1.7-8.5), followed by oropharyngeal cancer (OR: 3.2, 99% CI: 1.5-6.4) and the magnitude of this association is consistent with an infectious etiology. Stratification by high-risk infection subtypes also showed higher risks with HPV16 as well as HPV18 in all head and neck cancer sites.

Our results for nonfatal HPV-avertable cancers along with evidence from previous work³ on cervical cancer, all suggest the necessity of including HPV-based therapeutic vaccines before marriage, which are being developed for cervical cancer. Regular screening through visual inspection with acetic acid, and further referral for treatment^{9,10} after marriage may also benefit in the management of head and neck cancer, particularly in cases with oral cancer.

Aside from cancer control, HPV surveillance, through HPV vaccination programs, might be beneficial in HIV infection control. There is evidence¹¹ showing the association between HPV and HIV. Some studies have indicated that the risk of contracting HIV is twice as large in both men and women with HPV genotype.¹¹ This suggests a possibility of common factors involved in the development of both HPV and HIV. Therefore, further exploration of HPV incidence and its control via vaccination programs might allow an avenue for monitoring HIV infection as well, and subsequently enhance HIV control.

Yours sincerely, Jayadeep Patra Rajesh Dikshit Mehak Bhatia Chinthanie Ramasundarahettige Prabhat Jha

References

- Michaud DS, Langevin SM, Eliot M, Nelson HH, Pawlita M, McClean MD, Kelsey KT. High-risk HPV types and head and neck cancer. *Int J Cancer* 2014. doi: 10.1002/ijc.28811.
- Subramanian S, Sankaranarayanan R, Bapat B, et al. Cost effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. *Bull World Health Organ* 2009;87:200–6.
- Dikshit R, Gupta PC, Ramasundarahettige C, et al., and the Million Death Study Collaborators. Cancer mortality in India: a nationally representative survey. *Lancet* 2012;379:1807–16.
- Feller LL, Khammissa RR, Kramer BB, et al. Oral squamous cell carcinoma in relation to field precancerisation: pathobiology. *Cancer Cell Int* 2013;13:31.
- Chocolatewala NM, Chaturvedi P. Role of human papilloma virus in the oral carcinogenesis: an Indian perspective. J Cancer Res Ther 2009; 5:71-7.
- Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893–917.
- Koppikar P, de Villiers E, Mulherkar R. Identification of human papillomaviruses in tumors of the oral cavity in an Indian community. *Int J Cancer* 2005; 113:946–50.
- Patel KR, Vajaria BN, Begum R, et al. Prevalence of high-risk human papillomavirus type 16 and 18 in oral and cervical cancers in population from Gujarat, West India. J Oral Patho Med 2014; 43:293–7.
- Clifford GM, Smith JS, Plummer M, et al. Human Papillomavirus types in invasive cervical cancer worldwide: a meta analysis. Br J Cancer 2003;88:63– 73.
- Hobbs CGL, Sterne JAC, Bailey M, et al. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. *Clin Otolaryngol* 2006;31: 259–66.
- Houlihan CF, Larke NL, Watson-Jones D, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 2012;26:2211–22.

Grant sponsor: US National Institutes of Health; Grant numbers: R01-TW05991-01 and TW07939-01; Grant sponsor: Canadian Institutes of Health Research; Grant number: IEG-53506; Grant sponsor: Bill & Melinda Gates Foundation; Grant number: 57350 DOI: 10.1002/ijc.28998

History: Received 14 May 2014; Accepted 21 May 2014; Online 30 May 2014

We declare that we have no conflicts of interest.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. **Correspondence to:** Jayadeep Patra, PhD, Centre for Global Health Research, LKSKI, St. Michael's Hospital, Dalla Lana School of Public Health, University of Toronto, 30 Bond Street, Toronto, Canada, M5B 1W8, Tel.: +1 416 864 6060, Fax: +1 416 864 5256, E-mail: patraj@smh.ca